Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03814161
Other study ID # FREEDOM
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 20, 2019
Est. completion date December 1, 2023

Study information

Verified date March 2022
Source National University Hospital, Singapore
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Our study aims to compare 4 clinical frailty scores, namely Clinical Frailty Scale (CFS), Edmonton Frail Scale (EFS), FRAIL 5-item scale (FRAIL) and SARC-F Sarcopenia Score (SARC-F), which can potentially be adopted for daily practice in the busy ED. It is timely as we projected that we will be seeing more elderly patients attending the ED for various medical and surgical conditions. Their attendance at the ED would be a good opportunity to screen for frailty among them, and to intervene to prevent adverse outcomes such as ED re-attendance or subsequent hospitalisation that might lead to poor functional outcomes and higher dependence on step-down care facilities.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 211
Est. completion date December 1, 2023
Est. primary completion date December 1, 2022
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Elderly patients aged 65 years and above attending ED irrespective of reason for attendance. Exclusion Criteria: - Haemodynamically unstable patients - Inability to obtain informed consent - Inability to obtain reliable information from patient or caregiver (e.g. deafness, blindness, language barriers) - Vulnerable populations (e.g. prisoners) - Patients who are planned for hospital admission from the ED

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Singapore National University Hospital, Singapore Singapore

Sponsors (1)

Lead Sponsor Collaborator
National University Hospital, Singapore

Country where clinical trial is conducted

Singapore, 

References & Publications (1)

Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez Robledo LM, Rockwood K, von Haehling S, Vandewoude MF, Walston J. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013 Jun;14(6):392-7. doi: 10.1016/j.jamda.2013.03.022. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 1-month Adverse Event Occurrence (composite) Falls, ED re-attendance, hospital/ nursing home admission, decline in Activities of Daily Living and/or all-cause mortality At 1 month after index ED visit
Secondary 3-month Adverse Event Occurrence (composite) Falls, ED re-attendance, hospital/ nursing home admission, decline in Activities of Daily Living and/or all-cause mortality At 3 months after index ED visit